Novo's poorly received investor day and its need to pay over $1 billion to license outside technology are signs the company is losing its innovation edge exactly when Lilly is consolidating leadership in obesity drugs. A relative-value pair trade isolates

Verdict: The Lilly-Novo pair is live, but a coin-flip edge says size it, don't trust it

The strongest point for this trade is that the competitive divergence it bets on is real and current. Lilly's Q2 2026 revenue hit $23.0B, up 16.0% sequentially with trailing-year growth of 42.5% — the 76.8th percentile among 914 health-care peers — while Novo's FY2025 free cash flow fell 20.1% to DKK 59.0B and operating margin slipped to 41.3%. Both entry conditions are already armed: LLY at $1,181.89 sits above its $1,161.22 EMA with RSI at 64.1, and NVO at $38.62 trades below its $44.75 EMA with RSI at just 24.6, so the setup requires no waiting. The strongest point against is that the realized evidence is thin. The only completed window — nine months of daily bars — produced roughly 1.0% of return across 10 trades at a 50% win rate with a 5.6% maximum drawdown, and profits built to about 7% by early 2026 before giving nearly all of it back. Parameter sensitivity could not be run because NVO daily data was incomplete at compute time, so no robust parameter setup was established beyond the frozen rules. A new fact that would flip the verdict upward: a completed robustness check showing the setup holds across parameter variants. A new fact that would flip it downward: Lilly closing below about $1,161 or NVO reclaiming $44.75, which invalidates the legs. Our verdict: wait for confirmation. The trade-readiness bar is met, but a coin-flip hit rate on a thin sample does not yet justify full conviction sizing. **Conviction breakdown:** thesis support 62, trade readiness 70, risk quality 55, backtest evidence 40, fundamentals trend 60.

Trade now

Both entry conditions are in place today. LLY closed at $1,181.89, about $20.67 above its 50-day EMA of $1,161.22, and NVO closed at $38.62, about $6.13 below its 50-day EMA of $44.75. The momentum conditions are also met on both sides: LLY's 14-day RSI sits at 64.1, well above 50, while NVO's is 24.6, well below 50. So both the short leg on LLY and the long leg on NVO have fired, and the pair can be put on now rather than waited for. Risk is defined mechanically. The pair stop cuts at a 1.9% loss on the position and the pair take profit sits at 3.7%, an effective reward-to-risk of roughly 2-to-1. Structural invalidations sit just beyond the entries: an LLY close back below about $1,161 kills the short leg's premise, and an NVO reclaim of about $44.75 invalidates the long leg. There is also a 90-trading-day time stop, so this is not a hold-forever pair. Additional profit targets sit near LLY's second support around $1,079 and NVO's second resistance near $39.94. The evidence comes from a completed 9-month backtest on this pair: about a 1.0% total return across 10 trades, a 50% win rate, and a 5.6% maximum drawdown. That is a modest edge, not a moonshot — sizing capped at 20% per leg and roughly 1.9% risk per trade is what makes a 50% hit rate workable. One scope note: the rules were never re-tuned for this publication because Novo's daily price history was incomplete at compute time, so no robust parameter setup was established beyond the frozen rules shown here. "Wait" means something narrow here. If you missed today's trigger, the re-entry conditions are LLY holding above roughly $1,161 with RSI above 50, and NVO below roughly $44.75 with RSI below 50. If LLY breaks its EMA or NVO reclaims its own, do not chase — that is the exit, not a dip to buy.

Why the bull case still has support

The competitive-gap thesis shows up in the reported numbers. Lilly's Q2 2026 (period ended June 30, 2026) revenue of $23.0B rose 16.0% quarter over quarter from $19.8B, and its trailing-year revenue growth of 42.5% sits at the 76.8th percentile among 914 health care peers. Novo's FY2025 revenue grew just 6.4%, ranking at the 44.7th percentile. If the pair trade is meant to profit from Lilly consolidating leadership in obesity drugs while Novo struggles, the direction of these two growth rates is exactly what the idea needs — and it is what the filings show. Lilly is also strengthening while it grows. Its Q2 2026 gross margin expanded nearly 4 percentage points to 85.8%, the highest in the supplied series, and operating cash flow more than doubled to $10.7B from $5.3B the prior quarter. Debt-to-equity, at 1.62, remains well below the levels above 2.3 seen through 2023–2024. Novo, by contrast, saw FY2025 free cash flow fall 20.1% to DKK 59.0B, gross margin slip 3.7 points to 81.0%, and return on equity drop 17.6 points to 52.8%. The divergence the idea is trading is visible in cash quality, not just headlines — per the MarketWatch piece on the capital-markets day flop and the subsequent licensing deal, and CNBC's September 25 story on Novo's bet on its 'next chapter' as Lilly gains ground in GLP-1s. The realized backtest supports the pair structure itself. On the completed nine-month daily-bar evaluation, the strategy took 10 trades, won 50% of them, returned about 1.0%, and its worst peak-to-trough drawdown was 5.6%. For a market-neutral spread, a mid-single-digit maximum drawdown is a contained ride — this structure did not depend on the sector's direction to stay out of trouble. The thesis argues both legs share the same drug-market exposure, and the backtest result is consistent with a largely hedged profile rather than an outright biotech bet. The execution rules also fit the claim's tempo. The setup fades relative strength — shorting LLY when it is above its 50-day average with RSI above 50, or buying NVO when it is below its 50-day average with RSI below 50 — and exits on trend invalidation, a 90-bar time stop, support/resistance targets, and a volatility-adjusted 1.9% stop against a 3.7% take-profit. That is a mean-reversion wrapper around a secular competitive story: it monetizes the overshoots in each name while the underlying divergence between Lilly's 42.5% growth and Novo's 6.4% growth does…

Scores

• Conviction score breakdown: 57
• Thesis support: 62
• Trade readiness: 70
• Risk quality: 55
• Backtest evidence: 40
• Fundamentals trend: 60

Watch items

• LLY — Price vs 50-day EMA
• NVO — Price vs 50-day EMA
• LLY — RSI (14)
• NVO — RSI (14)
• NVO — Free cash flow (FY, DKK)
• LLY — Net margin (quarterly)
• LLY — Insider open-market net activity
• LLY — Next quarterly earnings